Affiris gets fresh funding
Vienna – Austrian Affiris AG has bagged EUR368.000 from the Michael J. Fox Foundation within the Parkinson’s Progression Markers Initiative for completion of preclinical development of its PD01 vaccine against Parkinson’s disease. PD01 targets alpha-synuclein, a protein that forms toxic protofibrils, causing oxidative damage and death of dopamin-producing neurons of Parkinson’s patients. Clinical trials are expected to begin this year, according to previous Affiris announcements.